Literature DB >> 7746621

An analysis of posterior segment complications after vitrectomy using the perfluorocarbon perfluoroperhydrophenanthrene (Vitreon). Vitreon Collaborative Study.

L K Verma1, G A Peyman, H Wafapoor, M D Greve, C M Millsap, S L Adile.   

Abstract

We report posterior segment complications encountered with the use of the liquid perfluorocarbon, perfluoroperhydrophenanthrene (Vitreon) as an intraoperative adjunct to vitreoretinal surgery in 640 patients participating in the Vitreon Collaborative Study. We also evaluated postoperative complications in 60 patients in whom Viteron was intentionally left inside the vitreous cavity for periods ranging from 5 days to 4 weeks as a short-term retinal tamponade. The five most common postoperative complications among these patients as a whole were recurrent retinal detachment, with or without proliferative vitreoretinopathy (11.28%); macular pucker (5.85%); fibrinous reaction (4%); residual Vitreon (3.85%); and vitreous hemorrhage (2.57%).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7746621

Source DB:  PubMed          Journal:  Ophthalmic Surg        ISSN: 0022-023X


  4 in total

1.  A surprising visual improvement following a prolonged 5-month retained subfoveal perfluorocarbon liquid.

Authors:  Daniel Sw Ting; Vicky Hsin-Ju Lu; Gavin Sw Tan; Edmund Ym Wong
Journal:  Int J Ophthalmol       Date:  2016-07-18       Impact factor: 1.779

2.  The effect of specific gravity of perfluorocarbon liquid on the retina after experimental vitreous substitution.

Authors:  Ulrike Stolba; Katharina Krepler; Michaela Velikay-Parel; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-07-17       Impact factor: 3.117

3.  Vitreous inflammation and macular edema secondary to perfluoro-n-octane toxicity.

Authors:  Fayna Rodríguez-González; Marta Tejera-Santana
Journal:  Rom J Ophthalmol       Date:  2021 Apr-Jun

Review 4.  Inflammation induced by perfluorocarbon liquid: intra- and postoperative use.

Authors:  Marta S Figueroa; Diego Ruiz Casas
Journal:  Biomed Res Int       Date:  2014-03-24       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.